AbbVie Inc.
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
AbbVie Inc.
Explore AbbVie
Core profile pages, annual revenue records, and related research hubs for this company.
Company History
Founded 2013 in North Chicago, Illinois
AbbVie was created on January 1, 2013, when Abbott Laboratories separated its research-based pharmaceutical business from its diversified healthcare operations. Richard A. Gonzalez became founding CEO, and the new company began trading on the NYSE under ticker ABBV.
Richard A. Gonzalez was AbbVie's founding CEO from the 2013 Abbott Laboratories spin-off through the 2024 CEO transition. His tenure covered Humira's peak, the Pharmacyclics and Allergan acquisitions, the beginning of U.S. Humira biosimilar competition, and the buildout of Skyrizi and Rinvoq as AbbVie's next immunology growth platform.
AbbVie began trading independently on the NYSE under ticker ABBV after Abbott Laboratories separated its research-based pharmaceutical business.
AbbVie completed the Pharmacyclics acquisition, adding Imbruvica and strengthening its oncology portfolio.
AbbVie completed the Allergan acquisition, adding Botox, Juvederm, aesthetics, Vraylar, Ubrelvy, Qulipta, and other assets.
Humira reached its final full-year peak before U.S. biosimilar competition reshaped AbbVie's revenue mix.
U.S. Humira biosimilars began competing, accelerating the shift toward Skyrizi, Rinvoq, aesthetics, neuroscience, and oncology.
Robert A. Michael succeeded Richard A. Gonzalez as AbbVie's CEO effective July 1, 2024.
AbbVie completed the ImmunoGen and Cerevel acquisitions, expanding oncology and neuroscience pipeline depth.
AbbVie reported $61.160 billion in FY2025 net revenue, with Skyrizi and Rinvoq together generating $25.866 billion.
AbbVie reported Q1 2026 net revenue of $15.002 billion, up 12.4% on a reported basis.
AbbVie acquired Pharmacyclics to add Imbruvica and build a stronger hematologic oncology business beyond Humira.
AbbVie acquired Allergan to add Botox, Juvederm, aesthetics, Vraylar, Ubrelvy, Qulipta, and other assets less tied to Humira.
AbbVie acquired ImmunoGen to add Elahere and strengthen its antibody-drug conjugate and solid tumor oncology platform.
AbbVie acquired Cerevel to deepen its neuroscience pipeline, especially emraclidine for schizophrenia and other clinical-stage assets.
AbbVie became an independent public company on January 1, 2013 after separating from Abbott Laboratories.
Abbott separated its research-based pharmaceutical business so AbbVie could focus on patented medicines while Abbott kept diversified healthcare products.
Humira was AbbVie's biggest early product and became one of the world's highest-selling medicines before biosimilar competition arrived.
The Allergan acquisition added Botox and aesthetics, while Skyrizi and Rinvoq became the growth platform after Humira lost exclusivity.
Richard A. Gonzalez led AbbVie from its 2013 launch until Robert A. Michael became CEO in 2024.